- Report
- May 2024
- 129 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- February 2021
- 50 Pages
Global
From €3090EUR$3,250USD£2,596GBP
- Report
- January 2019
- 18 Pages
Global
From €9507EUR$10,000USD£7,986GBP
The Aliqopa market is a subset of the larger lymphoma drug market, focusing on the development and commercialization of drugs for the treatment of B-cell non-Hodgkin lymphoma (NHL). Aliqopa is a monoclonal antibody that targets the CD20 antigen on B-cells, and is used in combination with chemotherapy to treat NHL. The Aliqopa market is characterized by a high degree of competition, with several companies developing and marketing similar drugs. The market is also characterized by a high degree of innovation, with companies developing new drugs and formulations to improve efficacy and safety.
Companies in the Aliqopa market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Janssen, Merck, Novartis, and Pfizer. Show Less Read more